U.S. Major Depressive Disorder (MDD) Market 2018: Segmented by Applications, End Users, Key Regions
U.S. Major Depressive Disorder (MDD) Market report 2018 - covers the market landscape and its growth prospects over the coming years till 2022
(EMAILWIRE.COM, August 15, 2018 ) U.S. Major Depressive Disorder (MDD) Market: Industry Analysis and Outlook (2018-2022) Report provides an extensive research on the fast-evolving Major Depressive Disorder (MDD) Market. It also gives competitive landscape of the leading companies with regional and analysis of the U.S. market till 2022.
The report discusses the major growth drivers and challenges of the market, covering the U.S. market. The report profiles the key players in the market including –
Pfizer Inc., AstraZeneca, Eli Lily and Company and Lundbeck.
Get inside view of the Report with Sample PDF @ http://www.orbisresearch.com/contacts/request-sample/2286216
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person’s ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
MDD is the most common mental disorder in the U.S. Approximately 16 million American adults suffer from the major depressive disorder and about one-third of the MDD patient remain untreated. The number of treated patients is projected to rise on account of better medical access and rising awareness regarding depression. There are few potential drugs in development that are being developed with improved efficacy and safety for the treatment of MDD and are expected to contribute significantly to the market growth in the U.S.
The U.S. MDD market is expected to grow in future due to –
Rising Aging Population, Growing MDD Prevalence, Growing Female Prevalence, Increasing Prescription Drugs Spending, High Unmet Needs and Escalating Mental Health Expenditure.
Key trends of this market include –
Rising Number of Mental Health Programs, Increasing Awareness and Rapid Drugs in Development and Direct to Customer Advertising.
However, there are some factors which can hinder the growth of the market which includes patent expiry of drugs, stringent regulations, side effects associated with antidepressants and availability of alternative therapies.
Request to Enquire before buying the Report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2286216
Table of Content:
1. Market Overview
1.1 Introduction
1.2 Causes of MDD
1.3 Symptoms of MDD
1.4 Diagnosis & Treatment of MDD
2. The U.S. MDD Market
2.1 The U.S. MDD Market by Value
2.2 The U.S. MDD Market by Drug Type
2.3 The U.S. Anti-Depressants Drugs Market
2.4 The U.S. Antipsychotics Drugs Market
2.5 The U.S. Top Psychiatric Drugs Revenue
2.6 The U.S. MDD Prevalence Forecast by Age
2.7 The U.S. MDD Patient Population Forecast
2.8 The U.S. MDD Treated Patient Population Forecast
2.9 The U.S. MDD Patient Treatment
2.10 The U.S. MDD Patient Population with TMS Criteria
2.11 The U.S. MDD Patient Share by Symptoms
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Growing Aging Population
3.1.2 Rising Female Population
3.1.3 Increasing Spending on Prescription Drugs
3.1.4 Increasing Prevalence of Depression
3.1.5 Growing Mental Health Expenditure
3.1.6 Unmet Need
3.2 Key Trends & Developments
3.2.1 Increasing Awareness for Depression
3.2.2 Direct to Customer Advertising
3.2.3 Rapid Acting Drugs In Development
3.2.4 Rising Number of Mental Health Programs
3.3 Challenges
3.3.1 Stringent Drug Regulations
3.3.2 Patent Expiry of Drugs
3.3.3 Complications and Side Effects associated with Anti-depressants
3.3.4 Availability of Other Therapies such as Meditation and Psychotherapy
4. Competitive Landscape
4.1 Global MDD Market
4.1.1 Revenue Comparison of Top Companies
4.1.2 Market Capitalization Comparison of Top Companies
4.1.3 Research & Development Expenditure Comparison of Top Companies
4.2 The U.S. MDD Market
4.2.1 The U.S. Anti-Depressants Market Comparison by Product Profile
4.2.2 The U.S. Anti-Psychotics Market Comparison by Product Profile
5. Company Profiles
5.1 Pfizer, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Eli Lilly and Company
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 AstraZeneca
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Lundbeck
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com
The report discusses the major growth drivers and challenges of the market, covering the U.S. market. The report profiles the key players in the market including –
Pfizer Inc., AstraZeneca, Eli Lily and Company and Lundbeck.
Get inside view of the Report with Sample PDF @ http://www.orbisresearch.com/contacts/request-sample/2286216
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person’s ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
MDD is the most common mental disorder in the U.S. Approximately 16 million American adults suffer from the major depressive disorder and about one-third of the MDD patient remain untreated. The number of treated patients is projected to rise on account of better medical access and rising awareness regarding depression. There are few potential drugs in development that are being developed with improved efficacy and safety for the treatment of MDD and are expected to contribute significantly to the market growth in the U.S.
The U.S. MDD market is expected to grow in future due to –
Rising Aging Population, Growing MDD Prevalence, Growing Female Prevalence, Increasing Prescription Drugs Spending, High Unmet Needs and Escalating Mental Health Expenditure.
Key trends of this market include –
Rising Number of Mental Health Programs, Increasing Awareness and Rapid Drugs in Development and Direct to Customer Advertising.
However, there are some factors which can hinder the growth of the market which includes patent expiry of drugs, stringent regulations, side effects associated with antidepressants and availability of alternative therapies.
Request to Enquire before buying the Report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2286216
Table of Content:
1. Market Overview
1.1 Introduction
1.2 Causes of MDD
1.3 Symptoms of MDD
1.4 Diagnosis & Treatment of MDD
2. The U.S. MDD Market
2.1 The U.S. MDD Market by Value
2.2 The U.S. MDD Market by Drug Type
2.3 The U.S. Anti-Depressants Drugs Market
2.4 The U.S. Antipsychotics Drugs Market
2.5 The U.S. Top Psychiatric Drugs Revenue
2.6 The U.S. MDD Prevalence Forecast by Age
2.7 The U.S. MDD Patient Population Forecast
2.8 The U.S. MDD Treated Patient Population Forecast
2.9 The U.S. MDD Patient Treatment
2.10 The U.S. MDD Patient Population with TMS Criteria
2.11 The U.S. MDD Patient Share by Symptoms
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Growing Aging Population
3.1.2 Rising Female Population
3.1.3 Increasing Spending on Prescription Drugs
3.1.4 Increasing Prevalence of Depression
3.1.5 Growing Mental Health Expenditure
3.1.6 Unmet Need
3.2 Key Trends & Developments
3.2.1 Increasing Awareness for Depression
3.2.2 Direct to Customer Advertising
3.2.3 Rapid Acting Drugs In Development
3.2.4 Rising Number of Mental Health Programs
3.3 Challenges
3.3.1 Stringent Drug Regulations
3.3.2 Patent Expiry of Drugs
3.3.3 Complications and Side Effects associated with Anti-depressants
3.3.4 Availability of Other Therapies such as Meditation and Psychotherapy
4. Competitive Landscape
4.1 Global MDD Market
4.1.1 Revenue Comparison of Top Companies
4.1.2 Market Capitalization Comparison of Top Companies
4.1.3 Research & Development Expenditure Comparison of Top Companies
4.2 The U.S. MDD Market
4.2.1 The U.S. Anti-Depressants Market Comparison by Product Profile
4.2.2 The U.S. Anti-Psychotics Market Comparison by Product Profile
5. Company Profiles
5.1 Pfizer, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Eli Lilly and Company
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 AstraZeneca
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Lundbeck
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results